全身霧化給藥系統 (Whole-body Nebulized Drug Delivery System)

全身式霧化給藥系統（AER）

產品說明
AER動物用全身式霧化給藥系統常用於建立動物疾病模型，進行過敏與吸入暴露相關研究。該系統可將液態藥物霧化並分散為可吸入氣溶膠，將實驗動物置於特定時間與氣體濃度條件下的實驗籠內，完成致敏與刺激過程，實現動物模型的建立；也可用作動物全身性吸入暴露實驗的暴露系統。

藥物霧化採用微孔濾網的高頻振盪技術，取代傳統的超音波與氣流式霧化。霧化頭中央具備數千個高精度微孔，透過高頻振動將液態藥物推送出微孔，形成氣溶膠。產生的氣溶膠顆粒大小約為1–5微米，能有效進入肺泡，有助於藥物在肺部深層沉積。

該系統主要由控制器、霧化模組與廢氣實驗籠三部分組成，提供單通道與雙通道版本可選。

霧化給藥系統亦可搭配不同尺寸的給藥籠，歡迎洽詢以獲得詳細資訊。

應用領域
可用於呼吸系統疾病之建模與霧化給藥，如支氣管氣喘、肺纖維化、慢性支氣管炎與肺損傷等。

參考文獻

[1]Fan Z,Zhou B,Liu Y,Sun W,Fang Y,Lu H,Chen D,Lu K,Wu X, Xiao T, Xie W, Bian Q."Optimization and Application of an Efficient and Stable Inhalation Exposure System for Rodents".[J].AAPS PharmSciTech.2022 Jan 6;23(1):50. doi:10.1208/s12249-021-02191-8.

[2]Jushan Zhang,Mo Xue,Rong Pan,Yujie Zhu,Zhongyang Zhang,Haoxiang Cheng,Johan L M Björkegren,Jia Chen,Zhiqiang Shi,Ke Hao"An e-cigarette aerosol generation, animal exposure and toxicants quantification system tocharacterize in vivo nicotine kinetics in arterial and venous blood"[J].bioRxiv preprint doi.

[3]Guolin Zhao,William Ho,Jinxian Chu, Xiaojian Xiong, Bin Hu,Kofi Oti Boakye-Yiadom,Xiaoyang Xu,Xue-Qing Zhang,Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of KRAS-Mutant Non-Small-Cell Lung Cancer,[J]ACS Applied Materials&Interfaces,2023-06-24,DOI:10.1021/acsami.3c05007.

[4]Liu X, Zhao L, Wang R, et al. TRPM2 exacerbates airway inflammation by regulating oxidized-CaMKⅡ in allergic asthma[J]. Heliyon, 2024, 10(1): e23634.

[5]Tian X, Gao Y, Ma W, et al. Establishment of an Inhalation Administration Non-invasive Murine Model for Rapidly Testing Drug Activity against Mycobacterium tuberculosis[J]. bioRxiv, 2024: 2024.02. 27.582260.

[6]Liu L, Tang Z, Zeng Q, et al. Transcriptomic Insights into Different Stimulation Intensity of Electroacupuncture in Treating COPD in Rat Models[J]. Journal of Inflammation Research, 2024: 2873-2887.

[7]Dong Y, Dong Y, Zhu C, et al. Targeting CCL2-CCR2 signaling pathway alleviates macrophage dysfunction in COPD via PI3K-AKT axis[J]. Cell Communication and Signaling, 2024, 22(1): 364.

[8]Shen S, Huang Q, Liu L, et al. GATA2 downregulation contributes to pro-inflammatory phenotype and defective phagocytosis of pulmonary macrophages in chronic obstructive pulmonary disease[J]. Aging (Albany NY), 2024, 16(19): 12928.

[9]Zou X, Huang Q, Kang T, et al. An integrated investigation of mitochondrial genes in COPD reveals the causal effect of NDUFS2 by regulating pulmonary macrophages[J]. Biology Direct, 2025, 20(1): 4.

[10]Tian X, Gao Y, Li C, et al. A novel non-invasive murine model for rapidly testing drug activity via inhalation administration against Mycobacterium tuberculosis[J]. Frontiers in Pharmacology, 2025, 15: 1400436.

[11]Liu K, Liu R, Zhang C, et al. Suzi Daotan Decoction alleviates asthmatic airway remodeling through the AMPK/SIRT1/PGC-1α signaling pathway and PI3K/AKT signaling pathway[J]. Scientific Reports, 2025, 15(1): 6690.

[12]Huang Q, Kang T, Shen S, et al. Extracellular vesicular delivery of ceramides from pulmonary macrophages to endothelial cells facilitates chronic obstructive pulmonary disease[J]. Cell Communication and Signaling, 2025, 23(1): 124.

[13]Zeng H, Liu X, Liu P, et al. Exercise's protective role in chronic obstructive pulmonary disease via modulation of M1 macrophage phenotype through the miR-124-3p/ERN1 axis[J]. Science Progress, 2025, 108(3): 00368504251360892.